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Background: This study will evaluate hypoxia, as a novel concept in the pathogenesis of diabetic macular oedema
(DMO). As the oxygen demand of the eye is maximum during dark-adaptation, we hypothesize that wearing
light-masks during sleep will cause regression and prevent the development and progression of DMO. The study
protocol comprises both an efficacy and mechanistic evaluation to test this hypothesis.
Method/Design: This is a phase III randomised controlled single-masked multicentre clinical trial to test the clinical
efficacy of light-masks at preventing dark-adaptation in the treatment of non-central DMO. Three hundred patients
with non-centre-involving DMO in at least one eye will be randomised 1:1 to light-masks and control masks
(with no light) to be used during sleep at night for a period of 24 months. The primary outcome is regression of
non-central oedema by assessing change in the zone of maximal retinal thickness at baseline on optical coherence
tomography (SD-OCT). Secondary outcomes will evaluate the prevention of development and progression of
DMO by assessing changes in retinal thickness in different regions of the macula, macular volume, refracted visual
acuity and level of retinopathy. Safety parameters will include sleep disturbance. Adverse events and measures
of compliance will be assessed over 24 months. Participants recruited to the mechanistic sub-study will have
additional retinal oximetry, multifocal electroretinography (ERG) and microperimetry to evaluate the role of hypoxia
by assessing and comparing changes induced by supplemental oxygen and the light-masks at 12 months.
Discussion: The outcomes of this study will provide insight into the pathogenesis of DMO and provide evidence
on whether a simple, non-invasive device in the form of a light-mask can help prevent the progression to
centre-involving DMO and visual impairment in people with diabetes.* Correspondence: senswathi@aol.com
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Diabetic retinopathy is the most common complication
of diabetes. Diabetic macular oedema (DMO), charac-
terised by leakage of fluid from compromised blood
vessels in the central retina, is the most frequent cause
of visual impairment in people with diabetes. DMO may
be central or non-central oedema. Non-central oedema
does not usually affect visual acuity. When it affects the
central 1 mm of the macula, it causes visual impairment.
Over 30% of eyes with untreated centre-involving macular
oedema lose 3 or more lines of vision by 5 years [1].
Patients with non-central DMO are monitored with
slit-lamp biomicroscopy and spectral domain optical co-
herence tomography (SD-OCT) every 4 to 6 months for
progression to centre-involving DMO. SD-OCT provides
information on the changes in the retinal thickness and
morphology of the retina due to DMO. Approximately
30% of these patients progress to centre-involving macu-
lar oedema by 12 months [2].
Treatment is available only when the DMO becomes
clinically significant or shows progression to the centre.
Laser treatment is the standard of care when the DMO
becomes clinically significant. Although laser treatment
reduces the risk of moderate visual loss by 50% at this
stage, it is not effective in restoring visual acuity and has
significant side effects that impact on the quality of life
of these people [1]. Newer treatment options of injec-
tions of vascular endothelial growth factor (VEGF) in-
hibitors are also available but only for centre-involving
DMO. These treatments are costly and cause significant
burden to the patient, their caregivers and the healthcare
system [3,4].
There are no treatment options for non-clinically signifi-
cant DMO except optimal control of diabetes and hyper-
tension. Laser photocoagulation may be performed for
non-central clinically significant macular oedema. The
natural history of the disease is to progress from non-
central to centre-involving DMO [2]. Therefore, there is a
substantial unmet need for both treatment and prevention
of progression of non-centre-involving DMO.
The exact pathogenesis of diabetic retinopathy and
DMO is uncertain. The rationale for this study is that in-
creased glucose is associated in various ways with a de-
crease in oxygen supply to the retina, and an increase in
oxygen demand [5]. This leads to increased hypoxia, and
an overproduction of VEGF, which damages the circula-
tion, and in doing so will further decrease retinal oxygen
supply in a vicious circle. Only at such a stage will all
the other known mechanisms that contribute to retinal
vascular damage operate and contribute to the various
clinical features of diabetic retinopathy. Rods use more
oxygen than any other cell in the body [5,6]. Oxygen is
required to support the extreme sensitivity to light that
develops during dark-adaptation. As a result, the oxygentension in the mitochondrial region of the rods in dark-
ness falls to zero. The exact mechanism is that in darkness
the rod outer segment membrane becomes extremely per-
meable to ions and water, which enter the cell and are
pumped out in the inner segment [7]. The resulting ‘dark
current’ is large and requires all the oxygen available in
the normal eye [8-10]. If retinal circulation is compro-
mised in any way, the hypoxia present in the outer retina
increases and spreads into the inner part.
Arden hypothesized that if dark-adaptation was pre-
vented, the rod dark current would never become maximal
and diabetic retinopathy would be alleviated by decreasing
the oxygen demand [8,9]. Since people only dark-adapt at
night during sleep, sleeping in an illuminated environment
should prevent or reverse the condition. In clinical trials it
is important to provide uniform illumination to each pa-
tient, so we have made ‘light-masks’ containing organic
light emitting diodes to illuminate the closed eyelids during
sleep. Sufficient low intensity light is transmitted by the lids
to reduce the dark current allowing the quantity of light
can be measured. It is also important that the masks are
comfortable to wear and do not disturb sleep.
The relationship of these SD-OCT changes in retinal
morphology and thickness to hypoxia has not been de-
termined. Similarly, the relation of the visual function to
hypoxia also remains unclear. This is the subject of the
mechanistic investigation.Objectives
The primary objective of the study is to explore whether
wearing light-masks during sleep at night reduces, rela-
tive to the control masks, the maximal zone macular
thickness at baseline as measured by SD-OCT in the
study eye of patients with non-centre-involving DMO at
24 months.
Secondary objectives include whether the effect of
light-masks, relative to control masks, can prevent the
progression of non-centre-involving DMO by assessing
the changes in retinal thickness in each region of the
macula, macular volume, macular morphology, retinop-
athy status, visual acuity and proportion of patients re-
quiring rescue laser or anti-VEGF treatment at 12 and
24 months. The safety and tolerability of the masks will
be assessed and will include measures of compliance and
questionnaires to assess the effect of the masks on sleep.
The mechanistic evaluation will explore and com-
pare the changes in retinal function induced by sup-
plemental oxygen and light-mask on multifocal ERG
(inner retina) and scotopic microperimetry (outer ret-
ina) at 12 months. The changes in oxygen saturation
in the retinal vessels will be assessed by retinal oxim-
etry using the Oxymap T1 Retinal Oximeter (Oxymap
Analyzer v.2.4.2, Reykjavik, Iceland
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This is a phase III randomised controlled single-masked
clinical trial that will evaluate the efficacy and safety of
light-masks in treating and preventing the progression
of non-centre-involving DMO. Three hundred patients
with non-centre-involving DMO in at least one eye will
be randomised 1:1 to light-masks and control masks
(with no light) to be used during sleep at night for a
period of 24 months. This basic study design and the as-
sociated clinical measurements are well-established, hav-
ing been successfully used in numerous previous clinical
trials of DMO. These include visual acuity and retinal
thickness measurements using SD-OCT every 4 months,
refracted visual acuity, retinal colour photographs, blood
pressure, glycosylated haemoglobin (HbA1c), Pittsburgh
Insomnia Rating Score [11] and Epworth Sleepiness
Scale [12] questionnaires to assess sleep at baseline, 12
and 24 months, adverse events and measures of compli-
ance at all 8 study visits over 24 months. Best correctedTable 1 CLEOPATRA - summary of study assessments
Baseline Week 1 Month 4 M






Concomitant medications x x x
HbA1c x
BP x
Pittsburgh Sleep Quality Index & Epworth
Sleepiness Scale
x x
BCVA (refraction at baseline, 12 and
24 months)
x x x
BCVA (repeated at baseline)a x
OCT - macular thickness protocolb x x x
Colour photographs - 3-field x
Mask compliance form x x x
Adverse events form x x x
Withdrawal form
Additional tests for mechanistic




BCVA: best corrected visual acuity; OCT: optical Coherence Tomography; mfERG: mu
within a field this denotes that the associated data will be collected at the identifie
repeated at baseline. bdenotes that OCT scans should be repeated at month 12 and
thicknesses on OCT will be used for the analysis.visual acuity will be repeated at baseline and SD-OCT
assessment will be done twice at 12 and 24 months to
assess inter-test variability. Participants recruited to the
mechanistic evaluation will have additional retinal oxim-
etry, multifocal ERG and microperimetry at baseline and
12 months. Please see visit schedules (Table 1) and study
flow diagram (Figure 1). At least 15 sites in England and
Wales will be participating in this study. Kings Clinical
Trials Unit (KCTU) is the co-ordinating centre. The
study has been approved by the National Research
Ethics Service Committee London - Dulwich (Ref: 13/
LO/0145).
Patient recruitment
Patients may be identified from diabetic retinopathy
screening programmes and medical retina clinics of the
trial sites and its satellite clinics. In addition, patients
may be referred by other medical retina consultants
from other hospitals to the Principal Investigators (PIs).onth 8 Month 12 Month 16 Month 20 Month 24
End of trial
isit 4 Visit 5 Visit 6 Visit 7 Visit 8 Withdrawal




x x x x x
x x x x x
x x x
x x x x x





ltifocal electroretinogram; BP: blood pressure. Note: where an ‘x’ is contained
d time point. adenotes that visual acuity with new refraction should be
24 to test for inter-test variability. The average of the two central subfield
Figure 1 Flow diagram of the CLEOPATRA trial. The flow diagram shows the patient flow through the period of the trial and includes the
mechanistic evaluation done at one site only.
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unnecessary trial procedures, it is recommended that
potential participants have an SD-OCT done at their
clinic visit or at a pre-screening clinic before trial
screening procedures are done to ensure exclusion of
eyes with centre-involving macular oedema defined as
central subfield > 300 μm.
We will report on the numbers of eligible patients in-
formed of the study, the numbers screened and the
numbers who were recruited into the study.Inclusion criteria are:
1. Subjects of either sex aged 18 years or over
2. Diagnosis of diabetes mellitus (type 1 or type 2). Any
one of the following will be considered to be
sufficient evidence that diabetes is present:
a. Current regular use of insulin for the treatment
of diabetes
b. Current regular use of oral anti-hyperglycaemic
agents for the treatment of diabetes
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3. Best corrected visual acuity in the study eye better
than 55 ETDRS letters (Snellen VA 6/24)
4. On clinical exam, retinal thickening due to early
DMO not involving the central 1000 μm of the
macula characterised by presence of microaneurysm,
exudates or oedema and OCT evidence of increased
retinal thickness in at least 1 non-central ETDRS
zone of ≥320 μm.
5. Previous macular laser, intravitreal steroids or
anti-VEGF treatment is permitted provided the last
laser treatment was done at least 4 months before
date of recruitment or anti-VEGF treatment was
done at least 2 months previously
6. Media clarity, pupillary dilation and subject
cooperation sufficient for adequate fundus photographs
7. Ability to return for study visits
8. Ability to give informed consent throughout the
duration of the study
Exclusion criteria include:
1. Clinical evidence of centre-involving macular
oedema that requires laser treatment within the next
6 months (central subfield on OCT > 300 μm)
2. Macular oedema is considered to be due to a cause
other than DMO
3. An ocular condition is present (other than diabetes)
that, in the opinion of the investigator, might affect
macular oedema or alter visual acuity during the
course of the study (for example, vein occlusion, uveitis
or other ocular inflammatory disease, neovascular
glaucoma, Irvine-Gass syndrome, and so on).
4. History of treatment for DMO at any time in the
past 4 months (such as focal/grid macular
photocoagulation, intravitreal or peribulbar
corticosteroids, anti-VEGF drugs, or any other
treatment) in the study eye
5. History of panretinal scatter photocoagulation in the
study eye
6. Active proliferative diabetic retinopathy in the study eye
7. A condition that, in the opinion of the investigator,
would preclude participation in the study
8. Corneal scarring, vitreous opacities, severe asteroid
hyalosis that would inhibit proper visualisation,
inability to be positioned in front of the SD-OCT
device, inability to understand the requirements of
the imaging, and nystagmus
9. Patients with active insomnia or any other relevant
sleep disturbances
Consent procedure
Eligible patients are informed about the study by a mem-
ber of the clinical team or research staff and writteninformation sheet is provided. After a consideration of at
least 24 hours, the patient is contacted to enquire
whether the patient is willing to participate in the study.
At the screening visit, a written information consent ap-
proved by the local ethics committee is obtained from
all participants before any trial-related procedures are
performed.
Randomisation
Randomisation will be via a bespoke 24-hour web-based
randomisation system hosted at the King’s Clinical Trials
Unit (KCTU). Patients will be randomised at the level of
the individual, using the method of minimisation incorp-
orating a random element. The minimisation factors
will be HbA1C (< 7.999% (63.89 mmol/mol or below)
or ≥8% (69.90 mmol/mol or above), perifoveal or parafo-
veal location of baseline zone of increased retinal thick-
ness of ≥320 μm (parafoveal zone 2 to 5 or perifoveal
zone 6 to 9) and study site. If both parafoveal and perifo-
veal zone thickening co-exist, it will be categorised as
parafoveal.
Patients may only be randomised into the study by an
authorised member of staff at the study site as detailed
on the delegation log. Participants may only be rando-
mised into the study once.
Trial interventions
Light-masks
The light-mask is manufactured by PolyPhotonix Medical
Ltd., Petec Netpark, Sedgfield, TS21 3FG, UK and will
be purchased from this company and supplied directly to
trial sites.
The light-mask is a device designed to deliver a precise
phototherapy to a user’s retina through closed eyelids.
The light-mask comes in two parts, a fabric mask and a
light emitting unit, or ‘Pod’. When worn, the Pod is
inserted into the fabric mask and placed over the pa-
tient’s eyes and attached using an adjustable Velcro
strap. The Pod contains two Organic Light Emitting
Diodes (OLEDs), which will be located over the eyes of
the patent when the light-mask is being worn. The fabric
mask is made of nylon, polyurethane and polyester.
These materials are non-toxic and are commonly used
in a wide variety of skin-contacting apparel. The Pod is
made from medical grade low-density polyethylene,
which has been tested and passed the relevant physio-
chemical and in vivo biological reactivity tests required
for the USP < 88 > Class VI requirements. The Pod and
fabric mask have been designed to be thin and flexible
and contoured to compliment the face and improve
comfort for the wearer.
The OLEDs are powered by two 3 V (CR2450) batter-
ies which power the device without the need for an ex-
ternal power source or recharging. At the end of the
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new fabric mask will be provided with each mask to
minimise contamination resulting from continued use.
The mask is time, date and touch sensitive. The mask
will only ‘work’ between pre-determined operational
windows - typically 8 pm to 10 am during the light-
mask’s lifetime. Within these times the mask can be
activated by a light touch. If worn within 3 minutes of
activation, sensors on the Pod will keep the mask illu-
minated for the night’s therapy. The times for which
the mask is worn will be logged for compliance ana-
lysis. The light-mask has CE certification as a Class 2a
device and its design and manufacture meet the standards
of ISO13485.
The design must permit the mask to be worn by
people with different head shapes and deliver rod exci-
tation efficiently. The spectral output is important and
should be matched as closely as possible to the re-
sponse spectrum of the rod cells. This has been tested
in two clinical trials. The first was a proof of concept
study, in which 12 patients slept in a mask containing
a chemoluminescent source which exposed one eye
only to light. The trial lasted 3 months. All found the
masks comfortable and the method of treatment
acceptable. There were no reports of adverse effects.
Measurements of colour contrast sensitivity and exam-
ination of standard fundus photographs showed that in
the ten for whom complete records were available,
colour vision improved and the area of retina covered
by microaneurysms and small dot haemorrhages de-
creased. These results were significant even though the
trial was very short and the numbers treated were so
few [13].
A second study was carried out using electronic
sources of light - blue-green light emitting diodes
(LEDs) to illuminate one eye. The electrical power of
the system was < 3 mW. Forty patients were recruited
and follow-up visits were at 3 and 6 months. All pa-
tients had early DMO in one eye and the other eye was
used as control. A total of 34 (85%) out of 40 patients
completed the study. Twenty-eight study eyes showed
intraretinal cysts compared with nine in the fellow
eyes. At 6 months, only 19 study eyes had cysts
while cysts were seen in 20 fellow eyes. The zone of
maximum thickness showed a reduction of retinal
thickness by 12 μm (95% CI 3 to 21, P = 0.01). The sec-
ondary outcomes of change in visual acuity, achromatic
contrast sensitivity, and microperimetric thresholds im-
proved significantly in study eyes and deteriorated in
fellow eyes [14].
The patients in this study will wear the light-mask
each night, receiving a maximum of 8 hours therapy per
night. The optical output of the mask has been tuned to
optimise scotopic intensity while minimising photopicintensity. The masks regulate the light output to a con-
stant luminosity x:
x ¼ 60cd=m2≤  ≤100cd=m2
This is well below toxic levels of luminosity but of
sufficient scotopic intensity to prevent dark-adaption.
Emission below 470 nm is less than 3% of total output
posing little or no risk of harm.
Every mask is capable of recording precisely when and
for how long it has been used, thus providing a very ac-
curate measure of compliance. Each mask will have a
predetermined lifetime and will need returning and re-
placing when this time expires. On the return of each
mask the compliance data can be downloaded and ana-
lysed. Patients will receive phone reminders and/or
counselling.Control masks
The control masks will consist of the CE marked device
with all internal electronics and functionality removed
and it is worn in the same way as the CE marked device.Blinding
Control participants will be provided with identical
dummy masks with no active light. However, it is likely
that patients in the control arm may not wear these
masks without illumination for a period of two years as
they are not masked to treatment allocation but all ef-
forts will be taken to ensure compliance. Primary out-
come assessors (optometrists and SD-OCT technicians)
will remain masked to treatment allocation. The optom-
etrists are the visual acuity examiners and OCT techni-
cians do the SD-OCT scans at all visits and both will be
masked to the participant study arm. The visual acuity
examiners will receive the participants into the visual
acuity lanes with a visual acuity case report form, study
number and detail of study eye and non-study eye to be
refracted, but with no previous subject records or case
report forms by which the subject treatment arm could
be identified. Similarly, the SD-OCT technicians will re-
ceive the subjects into the SD-OCT room on a specific
case report form that provides details of subject study
number and eye to be examined. The subjects will be
advised at enrolment that they must not discuss the
study arm they are in with the SD-OCT or Visual Acuity
examiner. The retinal photographs will be graded by
masked graders in the independent Reading Centre at
Moorfields Eye Hospital. This will avoid performance
and detection bias. We will describe the completeness of
outcome data for each outcome, including reasons for
attrition and exclusions from the analysis.
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All adverse events and side effects will be recorded in
the electronic case report form (eCRF) throughout the
study regardless of their severity or relation to study par-
ticipation. The light-masks are CE marked but the defi-
nitions of adverse events related to a non-CE marked
device will be used to classify and report the adverse
events in this study. No serious adverse events (SAEs)
are expected. The PI will submit an annual report of all
SAEs (expected and unexpected) to the Sponsor, and the
Research Ethics Committee. The Data Monitoring and
Ethics Committee (DMEC) will be provided with listings
of all SAEs on an on-going basis. The study may be pre-
maturely discontinued on the basis of new safety infor-
mation, or for other reasons given by the DMEC and/or
Trial Steering Committee (TSC), Sponsor, or Research
Ethics Committee concerned. Following 6 months of re-
cruitment, initial rates of recruitment will be used to
project total recruitment to ensure sufficient participants
to power the study. The TSC will advise on whether to
continue or discontinue the study and make a recom-
mendation to the Sponsor. If the study is prematurely
discontinued, active participants will be informed and no
further participant data will be collected.
Outcomes
The primary efficacy measure is the difference between
arms in the change from baseline in absolute retinal
thickness at the zone of maximum thickness as deter-
mined by OCT at 24 months.
The secondary efficacy parameters at 12 and 24
months are:
Efficacy parameters:
I. Difference between arms in the change from
baseline in absolute thickness at the zone of
maximum thickness as determined by OCT at
12 months.II. Other measures include:
1. Difference between arms in the change in retinal
thickness in the 9 ETDRS zones (parafoveal zones
2-5 and perifoveal zones 6-9) and macular
volume.
2. Difference between arm in morphological
characteristics of macular thickness
3. Difference between arms in the mean change in
visual acuity.
4. Difference between arms in the proportion of
centre-involving macular oedema within
24 months.
5. Difference between arms in the time to
occurrence of centre-involving macular oedema.
6. Difference between arms in the proportion
requiring macular laser or antiVEGF treatment.7. Difference between arms in the proportion of
participants that show progression of retinopathy
as measured by the ETDRS severity levels and
microaneurysm turnover.
8. Compliance rates in the light mask arm.
II. Assessment of Safety Parameters {XE “6.2
Procedures for Assessing Efficacy Parameters”}
1. Difference between arms in the measures of
sleep disturbance in terms of daytime sleepiness
and insomnia.
2. Difference between arms in ocular and systemic
adverse events and serious adverse events.
III. Assessment of Mechanistic Parameters {XE “6.2
Procedures for Assessing Efficacy Parameters”}
1. Change in P1 and N1 amplitudes and peak time
in multifocal ERG after supplemental oxygen
2. Change in retinal sensitivity in scotopic
microperimetry after supplemental oxygen.
3. To determine differences in change in P1 and N1
amplitudes and peak time in multifocal ERG after
light-masks and dummy masks at 12 months.
4. To determine differences in change in retinal
sensitivity in scotopic microperimetry after
light-masks and dummy masks at 12 months.
5. To correlate the changes induced by light-masks
and oxygen supplementation on retinal sensitivity
using oximetry.
Data collection
Data management procedures for the trial will be devel-
oped and overseen by King’s Clinical Trial Unit (KCTU).
All baseline and follow-up data will be entered on the
online InferMed MACRO electronic data capture (EDC)
system (http://www.infermed.com). This system is regu-
latory compliant (Good Clinical Practice (GCP) and the
EC Clinical Trial Directive). An eCRF using the MACRO
EDC will be programmed by KCTU in collaboration
with the Trial Manager, and Trial Statistician and
hosted on a dedicated secure server within King’s College
London. The eCRF system will have full audit trail, data
discrepancy functionality, database lock functionality, and
supports real time data cleaning and reporting.
The KCTU will provide training, essential documenta-
tion, and user support to the study centres, and on-site
audit and monitoring. A detailed Standard Operating
Procedure will cover data recording, online entry, check-
ing, central backup and storage. A regularly updated
coding manual will be developed to accompany the
study database. Each authorised research worker and PI
at each centre will have a unique username and pass-
word provided by the KCTU for the eCRF. The Trial
Manager will provide usernames and passwords to any
new researchers. Only those authorised by the Trial
Manager will be able to use the system.
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searchers in each study site prior to randomisation. Each
participant will be assigned a unique trial identification
number at the start of the assessment process. This
number will be written on all clinical assessment forms,
datasheets and databases used to record participant data.
Trial data will be first entered on to paper source data-
sheets provided to each centre during the preparation
phase. The datasheets will be immediately checked for
completeness and accuracy. If data queries arise, these
will be logged and followed up locally before data are
entered online. A hard copy of a record sheet linking pa-
tient identity, contact details and trial ID number for all
participants will be kept at each site. All data will be
kept secure at all times and maintained in accordance
with the requirements of the Data Protection Act and
archived locally according to clinical trial GCP regula-
tions and the host institutions additional procedures.
The study incorporates a range of data management
quality assurance functions. After written recording,
each research worker will transcribe data onto the eCRF
within one working week of a participant assessment.
After completion of all follow-ups and prompt entry of
data, the Trial Manager will review the data and issue
queries to be answered by the research worker. At the
end of the trial, the centre PI will review all the data for
each participant and provide electronic sign-off to verify
that all the data are complete and correct. At this point,
all data will be formally locked for analysis. At the end
of the trial, each centre will be supplied with a CD-ROM
containing the eCRF data for their centre. This will be
filed locally for any future regulatory or internal audit.
Statistical analysis
The primary outcome will be analysed using a two-sided
test from a linear mixed effect model for repeated mea-
sures across visits, which will enable a comparison
between participants receiving light-masks (active) and
control masks, with covariates for each follow-up visit of
baseline, randomisation stratifier and arm, and with a
random participant effect at each visit with unstructured
covariance matrix. The primary time-point will be
24 months. The 20% allowance for dropout (trial
withdrawal) is based on 18% early non-compliance
observed in the pilot study and we would expect a
reasonable proportion of non-compliers to provide pri-
mary time-point and intermediate visit outcome infor-
mation for this analysis.
We expect the DMEC would want to monitor study
power and we would regularly provide information such
as non-compliance, withdrawal, and variability of the
primary outcome with increasing certainty as increasing
proportions of the participants pass each of the 4-
monthly measurement points.The detailed statistical analysis plan will include an
additional sensitivity analysis involving all randomised
participants (intention to treat strategy) examining the
influence on the primary outcome analysis of opposing
optimistic and pessimistic scenarios for the intervention
effect in those withdrawing in each arm. We will adopt
the complier average causal effects (CACE) analysis
(under a missing at random assumption) as recom-
mended and outlined by Dunn et al. [15].
Linear mixed effect models for repeated measures (as
specified above for the primary outcome), logistic regres-
sion, and stratified Cox regression, will also be under-
taken to analyse secondary and mechanistic outcomes of
continuous, binary and time to occurrence type respect-
ively. Differences will be considered significant at P <
0.05. Differences between the groups will be estimated
with 95% confidence intervals. Repeated measure ana-
lyses (linear mixed effects models) will be used to docu-
ment trends over time.
Sample size calculation
With 300 patients (150 in each arm), we anticipate 240
to be followed up (20% dropout). This is sufficient to
provide 90% power to detect 15 μm in mean change of
retinal thickness at the zone of maximal thickness be-
tween arms using a 2-sided test, adjusting for baseline,
at the 5% level of significance, assuming a standard
deviation of 35.7 μm. The chosen detectable effect size
(retinal thickness of 15 μm) is both plausible, in terms of
being consistent with a confidence interval estimate for
this intervention in preceding research (Ruboxistaurin
trial protocol: B7A-MC-MBCU), and also minimally de-
tectable in terms of being distinguishable from test-
retest variation [25]. Detectable effect sizes for secondary
outcomes based on 240 followed up (for 90% power with
5% significance level) would be a between-arm difference
in mean outcome of a size that is equivalent to 0.42 of a
standard deviation.
Ethical issues
The conduct of this study will be in accordance with the
recommendations for physicians involved in research on
human subjects adopted by the 18th World Medical
Assembly, Helsinki 1964 and later revisions. This proto-
col and related documents have been approved by the
National Research Ethics Service Committee London -
Dulwich. Local approval will be sought before recruit-
ment may commence at the site. The Study Coordination
Centre will require a written copy of local approval
documentation before initiating each centre and accepting
participants into the study.
The main ethical issues in relation to this study are
the use of the light-masks. There are three visits that the
participants need to undergo in excess of standard of
Sivaprasad et al. Trials 2014, 15:458 Page 9 of 10
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be given to all those who require it. The precise risks
and benefits of participating in the study will be outlined
in patient information sheets, to be formulated with ser-
vice user involvement.
The patients who participate in the mechanistic tests
have to undergo non-invasive tests of oximetry, multi-
focal ERG and microperimetry. There are no known
risks with these tests.
All participants will be made aware of the results of
the study. If the study successfully establishes efficacy,
the participants will be informed that these light-masks
can be purchased but will not automatically be available
in the National Health Service (NHS), though the
treatment will be submitted for technology appraisal by
the National Institute of Clinical Excellence (NICE) if
deemed appropriate.
Time frame
We will recruit patients over 12 months and each par-
ticipant will be followed up over 24 months. The total
study period is 42 months.
Discussion
This trial is essential to confirm the role of hypoxia in
the pathogenesis of DMO. The importance of publishing
this extensive protocol is that it addresses a novel
approach to the management of non-central DMO. If
proven efficacious and safe, a light-mask is a simple
non-invasive device that can help prevent the most com-
mon cause of blindness during working life that is now
being managed by treatment options that have high dir-
ect and indirect costs to individuals and to the state.
Recent trials on the treatment of DMO have all fo-
cussed on centre-involving DMO and do not relate to
any questions about prophylactic treatment. The preven-
tion of any damage is obviously desirable and would lead
to considerable savings in treatment costs. Additionally
light-masks are simple devices, suitable for home use,
and could be provided even in remote areas where there
is no electricity supply. The benefit to those who cannot
obtain, or pay for, present high-technology treatments is
immense.
The strengths of the study are an appropriate design
and sample size and to achieve measureable outcomes.
The study is based on two proof-of-concept studies. The
control arm will provide new information on the natural
history of non-centre-involving DMO monitored using
SD-OCT over 24 months. This study on light-masks is
the first of its kind in the world. The limitation of the
study is the inability to design a double-masked study.
Trial status
The trial has started recruiting.Abbreviations
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